- Not yet recruitingPHASE3
COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"
This study looks at two existing drugs, anakinra and tocilizumab, to treat a rare, severe seizure condition called NORSE. It aims to find out which drug works better and when it should be given, as NORSE doesn't respond to usual treatments.
For: New Onset Refractory Status Epilepticus · New-Onset Refractory Status Epilepticus · Febrile Infection-Related Epilepsy Syndrome (FIRES)United States · Canada · France - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
An open-label, multicenter Phase 1/2 dose escalation and expansion study of THOR-707 as a single agent and as a combination therapy in adult subjects with advanced or metastatic solid tumors
This study is testing a new medicine, THOR-707, for people with advanced cancer. It aims to find the safest and most effective dose, and see how well it works alone or with other treatments to shrink tumours and improve health.
For: CancerSpain - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
This study is looking at a new medicine for people in the UK with Hodgkin Lymphoma that has come back or hasn't responded to other treatments. It aims to check if the new medicine, AZD7789, is safe, what effects it has, and if it helps in treating the cancer.
For: Relapsed/Refractory Classical Hodgkin LymphomaItaly · Denmark · Spain - RecruitingPHASE3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
This study is testing a new medicine, glofitamab, for people in the UK with a type of blood cancer called mantle cell lymphoma. It aims to see if glofitamab works better than standard treatments for those whose cancer has returned or isn't responding to past therapies.
For: LymphomaUnited States · Australia · Brazil - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)
This study compares a new cell therapy (Tisagenlecleucel) with standard treatments for adults with an aggressive type of lymphoma that has come back or not responded to previous therapy. Researchers want to see which treatment is better at stopping the cancer from growing.
For: Adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphomaNetherlands · Spain · Norway - AuthorisedTherapeutic use (Phase IV)
Concentration guided dose reduction versus standard dosing in tocilizumab treated heumatoid arthritis patients:a randomised, international, multicenter, non-inferiority trial
This study compares two ways of giving tocilizumab for rheumatoid arthritis: adjusting the dose based on blood levels vs. standard dosing. We want to see if adjusting the dose works just as well and is safe, helping to find the best treatment plan for patients.
For: Rheumatoid arthritisNetherlands - Active not recruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This study looks at new drug combinations for people with certain types of Non-Hodgkin's Lymphoma that have come back or not responded to previous treatments. It aims to check safety and how well the new treatments work.
For: Lymphoma, Non-HodgkinUnited States · Australia · Belgium - Active not recruitingPHASE1, PHASE2
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
This study looks at new drug combinations to treat B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. We want to see how safe and effective these new treatments are, especially when other treatments haven't worked.
For: B-cell Non-Hodgkin LymphomaUnited States · Belgium · Canada - Active not recruitingPHASE1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
This study looks at a new drug, Cevostamab, for people with multiple myeloma that has come back or not responded to previous treatments. It aims to check its safety, how it moves in the body, and if it helps when given alone or with other medicines.
For: Multiple MyelomaUnited States · Australia · Canada - RecruitingPHASE1, PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
This study looks at different treatment combinations for advanced breast cancer, including those that have spread or are hard to remove. Doctors want to see how well these new drug combinations work and if they are safe for patients.
For: Metastatic Breast CancerUnited States · Australia · France - RecruitingPHASE3
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
This study is looking at a new medicine called baricitinib for children aged 1 to 17 with a type of arthritis called systemic juvenile idiopathic arthritis (sJIA). It aims to see if baricitinib is safe and helps to reduce their symptoms.
For: Systemic Juvenile Idiopathic ArthritisArgentina · Belgium · Brazil - Active not recruitingPHASE1, PHASE2
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
This study looks at new drug combinations for follicular lymphoma. It checks how safe they are, how well they work, and how the body handles them. Researchers are comparing different ways to give one of the drugs.
For: Follicular LymphomaUnited States · China · France - RecruitingPHASE1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
This study looks at a new treatment called mosunetuzumab for chronic lymphocytic leukemia (CLL) that has come back or not responded to previous treatments. It checks how safe it is, how well it works, and how the body handles it, sometimes used with another drug, venetoclax.
For: Chronic Lymphocytic LeukemiaUnited States · Australia · China - Active not recruitingPHASE3
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This study looks at a new drug, glofitamab, combined with standard chemotherapy (GemOx) for people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatments. It compares this new combination to a standard treatment.
For: Diffuse Large B-cell LymphomaUnited States · Australia · Belgium - RecruitingPHASE1
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
This study is looking at a new medicine called RO7507062 for people with Systemic Lupus Erythematosus (SLE). It aims to see how safe the medicine is, how well bodies cope with it, and what it does in the body. This is an early stage study.
For: Systemic Lupus ErythematosusColombia · France · Germany - RecruitingPHASE3
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
This study looks at new treatments for a severe type of childhood arthritis called Systemic Juvenile Idiopathic Arthritis (sJIA). It compares upadacitinib with an existing treatment, tocilizumab, to see how well they work and if they cause any side effects in children aged 1 to 17.
For: Juvenile Idiopathic ArthritisUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A PHASE 2 MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN SUBJECTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA (INHL)
This study looks at a new type of cell therapy, Yescarta, for people with certain types of slow-growing non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. Researchers are checking how well it works and if it's safe over many years.
For: Follicular Lymphoma · Marginal Zone Lymphoma · Indolent Non-Hodgkin LymphomaFrance - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2a, Open-label, Dose Escalation Trial of GEN3017 with Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma
This study is testing a new medicine called GEN3017 for people with Hodgkin or non-Hodgkin lymphoma. It's an early-stage trial looking at safe doses and checking for side effects, as well as seeing how well the treatment shrinks the cancer.
For: Hodgkin lymphoma or non-Hodgkin lymphomaGermany · Denmark · Italy - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
This study is testing a new medicine, TAK-280, for people with advanced cancer that can't be removed by surgery. It's an early-stage study looking at how safe the drug is, what side effects it might cause, and how the body handles it. We also want to see if it helps shrink tumours.
For: Unresectable Locally Advanced or Metastatic CancerSpain · France - AuthorisedTherapeutic exploratory (Phase II)
A multi-center single arm Phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma
This study looks at a new type of cell therapy, called MB-CART2019.1, for people with a specific type of lymphoma that has come back or hasn't responded to other treatments. It checks how safe and effective it is.
For: Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL)Hungary · Croatia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 study of durcabtagene autoleucel, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and refractory multiple myeloma
This study is testing a new cell therapy called durcabtagene autoleucel for adults with multiple myeloma that has come back or isn't responding to other treatments. It aims to see how well the treatment shrinks the cancer and improves patients' health.
For: Adult patients with relapsed and refractory multiple myelomaSpain · Greece · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease
This study looks at new ways to treat serious, ongoing inflammatory diseases that haven't responded to other treatments. Researchers are testing different existing medicines to see which ones work best to reduce inflammation and improve symptoms in patients with complex conditions.
For: Patients displaying a non-classified · severe and resistant inflammatory diseaseFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Efficacy of Tocilizumab in association to steroids in giant cell arteritis with cerebro-vascular involvement patients (ToGiAS). A french prospective multicentre randomized versus placebo phase III trial (TOGIAC)
This study looks at a medicine called tocilizumab, together with common steroid treatments, for people in the UK with a specific type of giant cell arteritis that affects the brain. It aims to see if this combination can prevent new problems and help people get better.
For: Giant cell arteritis with Cerebro-vascular involvementFrance - Active not recruitingPHASE1
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
This study is looking at a new medicine called Runimotamab for people with certain advanced HER2-positive cancers. It aims to see if it's safe and how it works, both alone and with other treatments like Trastuzumab.
For: Solid TumorsUnited States · Australia · Belgium - RecruitingPHASE1, PHASE2
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
This study is testing a new drug, ubamatamab, alone or with cemiplimab, for recurrent ovarian or endometrial cancer. It aims to see how safe it is, how it works in the body, and if it can help treat these cancers.
For: Recurrent Ovarian Cancer · Recurrent Fallopian Tube Cancer · Recurrent Primary Peritoneal CancerUnited States · Australia · Belgium - RecruitingPHASE3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
This study, called REMAP-CAP, looks at different treatments for serious lung infections like pneumonia, flu, and COVID-19 in adults needing intensive care. It aims to find out which treatments work best to help patients recover.
For: Community-acquired Pneumonia, Influenza, COVID-19United States · Australia · Belgium - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
This study looks at a new treatment called BMS-986353 for severe Systemic Sclerosis. It compares this new treatment with standard care to see if it's more effective and safe for people with this condition.
For: Systemic SclerosisUnited States · Belgium · Canada - RecruitingPHASE1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
This study is testing new combinations of medicines for a type of blood cancer called Non-Hodgkin Lymphoma. It aims to see how safe and effective these new treatments are, and how the body handles them. It's for people whose cancer hasn't responded well to previous treatments.
For: Non-Hodgkin LymphomaUnited States · Israel · Italy - AuthorisedTherapeutic exploratory (Phase II)
PALETTE - Adaptive platform trial for personalisation of sepsis treatment in children and adults: a multi-national, treatable traits-guided, adaptive, exploratory, bayesian basket trial
This study is looking for better ways to treat sepsis in adults. It's testing several existing medicines to see if any work well for different types of sepsis. The main goals are to improve survival and help patients recover without needing machines to support their bodies.
For: SepsisFrance - AuthorisedTherapeutic exploratory (Phase II)
STARS - Prospective, bayesian, randomized, controlled, open-label, parallel-group, phase II interventional study evaluating efficacy and safety of secukinumab versus standard of care in active severe Takayasu patients
This study, called STARS, is looking at a new medicine for Takayasu arteritis, a condition that makes blood vessels inflamed. Researchers want to see if this medicine, called secukinumab (Cosentyx), works better and is safer than usual treatments for severe forms of the disease.
For: TAkayasu ARteritiSFrance - RecruitingPHASE3
Randomised Evaluation of COVID-19 Therapy
The RECOVERY trial looks at treatments for serious lung infections like pneumonia, including COVID-19. It helps doctors find the best ways to help hospitalised patients get better and reduce their risk of dying. Many treatments have been tested, and some have been found to be very helpful.
For: PneumoniaBelgium · Estonia · France - Active not recruitingPHASE1, PHASE2
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This study looks at new drug combinations for adults with a type of blood cancer called Non-Hodgkin's Lymphoma that has come back or not responded to previous treatments. It aims to find the safest dose and see how well these new treatments work.
For: Non-Hodgkins LymphomaBelgium · Denmark · Israel